{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T18:39:51Z","timestamp":1773772791566,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,1,29]],"date-time":"2014-01-29T00:00:00Z","timestamp":1390953600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1007\/s40618-013-0038-5","type":"journal-article","created":{"date-parts":[[2014,1,28]],"date-time":"2014-01-28T09:33:50Z","timestamp":1390901630000},"page":"229-232","source":"Crossref","is-referenced-by-count":7,"title":["The effect of zoledronic acid on the fracture risk in men with osteoporosis"],"prefix":"10.1007","volume":"37","author":[{"given":"R.","family":"Spiegel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. P.","family":"Nawroth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Kasperk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,1,29]]},"reference":[{"key":"38_CR1","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1056\/NEJMoa1204061","volume":"367","author":"S Boonen","year":"2012","unstructured":"Boonen S, Reginster JY, Kaufman JM et al (2012) Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med 367:1714\u20131723","journal-title":"N Engl J Med"},{"key":"38_CR2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1210\/jc.2012-3099","volume":"98","author":"S Jehle","year":"2013","unstructured":"Jehle S, Hulter HN, Krapf R (2013) Effect of potassium citrate on bone density, microarchitecture, and fracture risk in healthy older adults without osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 98:207\u2013217","journal-title":"J Clin Endocrinol Metab"},{"key":"38_CR3","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.bone.2012.06.016","volume":"51","author":"S Boonen","year":"2012","unstructured":"Boonen S, Lorenc RS, Wenderoth D et al (2012) Evidence for safety and efficacy of risedronate in men with osteoporosis over 4\u00a0years of treatment: results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study. Bone 51:383\u2013388","journal-title":"Bone"},{"key":"38_CR4","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00223-011-9543-8","volume":"89","author":"JD Adachi","year":"2011","unstructured":"Adachi JD, Lyles K, Boonen S et al (2011) Subtrochanteric fractures in bisphosphonate-naive patients: results from the HORIZON-recurrent fracture trial. Calcif Tissue Int 89:427\u2013433","journal-title":"Calcif Tissue Int"},{"key":"38_CR5","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1111\/j.1532-5415.2011.03666.x","volume":"59","author":"S Boonen","year":"2011","unstructured":"Boonen S, Orwoll E, Magaziner J et al (2011) Once-yearly zoledronic acid in older men compared with women with recent hip fracture. J Am Geriatr Soc 59:2084\u20132090","journal-title":"J Am Geriatr Soc"},{"key":"38_CR6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","volume":"18","author":"ES Orwoll","year":"2003","unstructured":"Orwoll ES, Scheele WH, Paul S et al (2003) The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9\u201317","journal-title":"J Bone Miner Res"},{"key":"38_CR7","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1359\/jbmr.081214","volume":"24","author":"S Boonen","year":"2009","unstructured":"Boonen S, Orwoll ES, Wenderoth D et al (2009) Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res 24:719\u2013725","journal-title":"J Bone Miner Res"},{"key":"38_CR8","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1002\/jbmr.119","volume":"25","author":"ES Orwoll","year":"2010","unstructured":"Orwoll ES, Miller PD, Adachi JD et al (2010) Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5\u00a0mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res 25:2239\u20132250","journal-title":"J Bone Miner Res"},{"key":"38_CR9","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.bone.2009.12.034","volume":"46","author":"ES Orwoll","year":"2010","unstructured":"Orwoll ES, Binkley NC, Lewiecki EM et al (2010) Efficacy and safety of monthly ibandronate in men with low bone density. Bone 46:970\u2013976","journal-title":"Bone"},{"key":"38_CR10","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1056\/NEJM200008313430902","volume":"343","author":"E Orwoll","year":"2000","unstructured":"Orwoll E, Ettinger M, Weiss S et al (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604\u2013610","journal-title":"N Engl J Med"},{"key":"38_CR11","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1359\/jbmr.090216","volume":"24","author":"A Fahrleitner-Pammer","year":"2009","unstructured":"Fahrleitner-Pammer A, Piswanger-Soelkner JC, Pieber TR et al (2009) Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial. J Bone Miner Res 24:1335\u20131344","journal-title":"J Bone Miner Res"},{"key":"38_CR12","doi-asserted-by":"crossref","first-page":"5252","DOI":"10.1210\/jcem.86.11.7988","volume":"86","author":"JD Ringe","year":"2001","unstructured":"Ringe JD, Faber H, Dorst A (2001) Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Metabol 86:5252\u20135255","journal-title":"J Clin Endocrinol Metabol"},{"key":"38_CR13","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s00296-003-0388-y","volume":"24","author":"JD Ringe","year":"2004","unstructured":"Ringe JD, Dorst A, Faber H, Ibach K (2004) Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int 24:110\u2013113","journal-title":"Rheumatol Int"},{"key":"38_CR14","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s00223-001-1060-8","volume":"69","author":"DM Reid","year":"2001","unstructured":"Reid DM, Adami S, Devogelaer JP, Chines AA (2001) Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int 69:242\u2013247","journal-title":"Calcif Tissue Int"},{"key":"38_CR15","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group. Lancet 348:1535\u20131541","journal-title":"Lancet"},{"key":"38_CR16","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822","journal-title":"N Engl J Med"},{"key":"38_CR17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2165\/11587570-000000000-00000","volume":"71","author":"JY Reginster","year":"2011","unstructured":"Reginster JY (2011) Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs 71:65\u201378","journal-title":"Drugs"},{"key":"38_CR18","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"MR McClung","year":"2001","unstructured":"McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women: Hip Intervention Program Study Group. N Engl J Med 344:333\u2013340","journal-title":"N Engl J Med"},{"key":"38_CR19","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1055\/s-0032-1321808","volume":"120","author":"IH Tarner","year":"2012","unstructured":"Tarner IH, Erkal MZ, Obermayer-Pietsch BM et al (2012) Osteometabolic and osteogenetic pattern of Turkish immigrants in Germany. Exp Clin Endocrinol Diabetes 120:517\u2013523","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"38_CR20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1055\/s-0032-1333260","volume":"121","author":"O Soucek","year":"2013","unstructured":"Soucek O, Lebl J, Zapletalova J et al (2013) Bone geometry and volumetric bone density at the radius in patients with isolated SHOX deficiency. Exp Clin Endocrinol Diabetes 121:109\u2013114","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"38_CR21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1055\/s-0031-1297993","volume":"120","author":"C Bernecker","year":"2012","unstructured":"Bernecker C, West TB, Mansmann G et al (2012) Hypercortisolism caused by ritonavir associated inhibition of CYP 3A4 under inhalative glucocorticoid therapy. 2 case reports and a review of the literature. Exp Clin Endocrinol Diabetes 120:125\u2013127","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"38_CR22","doi-asserted-by":"crossref","unstructured":"Gl\u00fcer CC, Marin F, Ringe JD, et al (2013) Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of teh EuroGIOPs trial. J Bone Miner Res. doi: 10.1002\/jbmr.1870 . [Epub, ahead of print]","DOI":"10.1002\/jbmr.1870"},{"key":"38_CR23","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1055\/s-0032-1321811","volume":"120","author":"P Toelle","year":"2012","unstructured":"Toelle P, Peterli R, Zobel I et al (2012) Risk factors for secondary hyperparathyreoidism after bariatric surgery: a comparison of 4 different operations and of vitamin D-receptor-polymorphism. Exp Clin Endocrinol Diabetes 120:629\u2013634","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"38_CR24","unstructured":"Kasperk C (2013) Zweckm\u00e4\u00dfige medikament\u00f6se Therapie der Osteoporose. KVBW Verordnungsforum"},{"key":"38_CR25","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1055\/s-0032-1309009","volume":"120","author":"L Zhang","year":"2012","unstructured":"Zhang L, Yang M, Liu D et al (2012) The rhPTH (1-34), but not elcatonin, increases bone anabolic efficacy in postmenopausal women with osteoporosis. Exp Clin Endocrinol Diabetes 120:361\u2013366","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"38_CR26","doi-asserted-by":"crossref","unstructured":"Walker MD, Cusano NE, Sliney J Jr, et al (2012) Combination therapy with risedronate and teriparatide in male osteoporosis. Endocrine. [Epub, ahead of print]","DOI":"10.1007\/s12020-012-9819-4"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-013-0038-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-013-0038-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-013-0038-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T02:53:09Z","timestamp":1565146389000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-013-0038-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,29]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["38"],"URL":"https:\/\/doi.org\/10.1007\/s40618-013-0038-5","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,29]]}}}